Amgen Appoints David W. Meline Executive Vice President and Chief Financial
THOUSAND OAKS, Calif., June 9, 2014
THOUSAND OAKS, Calif., June 9, 2014 /PRNewswire/ --Amgen (NASDAQ:AMGN) today
announced the appointment of David W. Meline as executive vice president and
chief financial officer (CFO), effective July 21, 2014. He will be responsible
for Amgen's finance and investor relations operations, reporting to Robert A.
Bradway, chairman and chief executive officer. Meline will succeed Michael A.
Kelly, who served as acting CFO since January 2014.
Meline, 56, joins Amgen from 3M Company, where he most recently served as
senior vice president and CFO, responsible for all financial activities for 3M
across 70 countries of operation.
Previously, Meline held numerous leadership positions at General Motors,
living and working on five continents during his tenure. Meline received his
Master of Business Administration in finance from the University of Chicago,
his Master of Science in economics from the London School of Economics and his
Bachelor of Science in mechanical engineering from Iowa State University.
Bradway said,"David's leadership talent and broadinternational
experiencewill be invaluable toAmgen as we execute our strategy for long
term growth andbringourpipeline of medicines toward commercialization in a
number of new markets.I am delighted to welcome him to the team."
Amgen is committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer since 1980,
Amgen has grown to be the world's largest independent biotechnology company,
has reached millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on
CONTACT: Amgen, Thousand Oaks
David Caouette, 805-447-2661 (media)
Arvind Sood, 805-447-1060 (investors)
Logo - http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
Press spacebar to pause and continue. Press esc to stop.